MANNIN RESEARCH EXECUTIVES ATTENDING OIS@AAO 2016 & AAO
Mannin Research Inc will participate at the the Ophthalmology Innovation Summit and the American Academy of Ophthalmology Annual Meeting in Chicago IL.
Mannin Research Inc. will be attending the Ophthalmology Innovation Summit (OIS@AAO 2016), which takes place on October 13th 2016 in Chicago, Illinois. The OIS facilitates meaningful interactions and business partnerships between physicians, entrepreneurs, investors, and industry executives who are driving ophthalmic innovation.
The Ophthalmology Innovation Summit is held in conjunction with the American Academy of Ophthalmology Annual Meeting (AAO 2016). The American Academy of Ophthalmology is the world’s largest association of eye physicians and surgeons. The AAO Annual Meeting runs from October 14-18. Mannin Research executives will be attending both OIS and AAO this year to meet with academics and industry professionals.
The meeting provides Mannin executives the opportunity to further explore business development goals and other collaborative opportunities for the MAN-01 program for treatment of glaucoma.
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.